Skip to content

Observation on the curative effect of Qingdu powder applied by Yi medicine on dampness-heat obstruction syndrome of acute gouty arthritis

Observation on the curative effect of Qingdu powder applied by Yi medicine on dampness-heat obstruction syndrome of acute gouty arthritis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042148
Enrollment
Unknown
Registered
2021-01-14
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gouty Arthritis

Interventions

Sponsors

Yunnan Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Those who meet the diagnostic criteria of Western medicine for acute gouty arthritis and the syndrome differentiation criteria of traditional Chinese medicine for dampness-heat obstruction. 2.The age range is from 18 to 70, and gender is not limited. 3.The course of the attack is less than 5 days. 4.No ulceration of the skin at the site of arthritis. 5.The joint pain sites are knee joint, ankle joint or the first metatarsophalangeal joint. 6.Patients are willing to be tested and give informed consent.

Exclusion criteria

Exclusion criteria: 1. Secondary gout, joint lesions caused by diseases such as rheumatoid arthritis, silver-dural arthritis, pseudogout and lupus erythematosus. Chemotherapy, radiotherapy, acute obstructive nephropathy and other joint lesions; 2. Patients with advanced deformity, disability, loss of labor force, and cardiovascular and cerebrovascular diseases induced by pain; 3. Severe heart, brain, liver, kidney and other complications or other serious primary diseases, such as tumor or AIDS; 4. Pregnant and lactating women; 5. Unbearable severe joint pain (patient rating 10); 6. People with mental or legal disabilities; 7. People with allergic constitution (especially those who are allergic to plaster) and known to be allergic to the components of this medicine; 8. According to the researcher's judgment, other lesions that reduce the possibility of enrolment or complicate enrolment, such as frequent changes in the work environment, may easily lead to loss of follow-up; 9. Participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Erythrocyte Sedimentation Rate;Blood Routine Examination;C Reactive Protein;Musculoskeletal Ultrasound;Pain degree VAS score;TCM syndrome scoring;

Countries

China

Contacts

Public ContactChen Yanlin

Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine.

ynkmpzj@126.com+86 13888340962

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026